Indoco Remedies · NSE: INDOCO · BSE: 532612
Q1 FY26 results · Apr–Jun 2025
Indoco Remedies reported revenue from operations of ₹437.89 crore (up 1.5% from Q1 FY25) and net loss of ₹36.35 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 437.89 | 431.49 | +1.5% | 390.21 | +12.2% |
| Other income | 1.63 | 1.03 | +58.3% | 2.02 | −19.3% |
| Total income | 439.52 | 432.52 | +1.6% | 392.23 | +12.1% |
| Profit before tax | (36.66) | 6.97 | Turned loss | (45.52) | Loss narrowed |
| Net profit for the period | (36.35) | 1.82 | Turned loss | (41.34) | Loss narrowed |
| Attributable to shareholders of the company | (35.79) | 2.62 | Turned loss | (40.39) | Loss narrowed |
| EPS, basic (₹) | (3.94) | 0.20 | Turned loss | (4.48) | Loss narrowed |
| Net margin (%) | -8.3 | 0.4 | -10.6 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 392.53 | 401.43 | −2.2% | 347.25 | +13.0% |
| Other income | 5.58 | 3.52 | +58.5% | 6.50 | −14.2% |
| Total income | 398.11 | 404.95 | −1.7% | 353.75 | +12.5% |
| Profit before tax | (28.40) | 19.51 | Turned loss | (30.90) | Loss narrowed |
| Net profit for the period | (28.06) | 14.95 | Turned loss | (26.24) | Loss widened |
| EPS, basic (₹) | (3.04) | 1.62 | Turned loss | (2.85) | Loss widened |
| Net margin (%) | -7.1 | 3.7 | -7.6 |
Consolidated
- Filed with BSE
- 24 Jul 2025, 13:38 IST
- Board meeting
- 24 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jul 2025, 13:38 IST
- Board meeting
- 24 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE